A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits

Human Molecular Genetics

Volumn 24, Issue 9, 2015, Pages 2604-2614

  Aharony, Israel ^a   Ehrnhoefer, Dagmar E ^b   Shruster, Adi ^a   Qiu, Xiaofan ^b   Franciosi, Sonia ^b   Hayden, Michael R ^b   Offen, Daniel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 6; CASPASE INHIBITOR; CELL PENETRATING PEPTIDE; ED 11 PEPTIDE; HUNTINGTIN; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG; HUNTINGTON PROTEIN, MOUSE; NERVE PROTEIN; NUCLEAR PROTEIN; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CELL PROTECTION; COGNITIVE DEFECT; CONTROLLED STUDY; CONVALESCENCE; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; EMBRYO; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MOTOR PERFORMANCE; MOUSE; MUTANT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PSYCHOMOTOR DISORDER; TREATMENT RESPONSE; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; FEMALE; GENETICS; HUNTINGTON DISEASE; MALE; METABOLISM; MUTATION; PATHOPHYSIOLOGY; PSYCHOMOTOR PERFORMANCE;

ANIMALS; BEHAVIOR, ANIMAL; CASPASE 6; CASPASE INHIBITORS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; HUNTINGTON DISEASE; MALE; MICE; MUTATION; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; PEPTIDES; PSYCHOMOTOR PERFORMANCE;

EID: 84941954604     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv023     Document Type: Article

References (34)

1. Ross, C.A. and Tabrizi, S.J. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol., 10, 83-98.
2. Goldberg, Y.P., Nicholson, D.W., Rasper, D.M., Kalchman, M. A., Koide, H.B., Graham, R.K., Bromm, M., Kazemi-Esfarjani, P., Thornberry, N.A., Vaillancourt, J.P. et al. (1996) Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat. Genet., 13, 442-449.
3. Wellington, C.L., Ellerby, L.M., Gutekunst, C.A., Rogers, D., Warby, S., Graham, R.K., Loubser, O., van Raamsdonk, J., Singaraja, R. and Yang, Y.Z. (2002) Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci., 22, 7862-7872.
4. Graham, R.K., Deng, Y., Carroll, J., Vaid, K., Cowan, C., Pouladi, M.A., Metzler, M., Bissada, N., Wang, L., Faull, R.L.M. et al. (2010) Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. J. Neurosci., 30, 15019-15029.
5. Warby, S.C., Doty, C.N., Graham, R.K., Carroll, J.B., Yang, Y., Singaraja, R.R., Overall, C.M. and Hayden, M.R. (2008) Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum. Mol. Genet., 17, 2390-2404.
6. Ehrnhoefer, D.E., Skotte, N.H., Ladha, S., Nguyen, Y.T.N., Qiu, X., Deng, Y., Huynh, K.T., Engemann, S., Nielsen, S.M., Becanovic, K. et al. (2014) p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Hum. Mol. Genet., 23, 717-729.
7. Graham, R.K., Deng, Y., Slow, E.J., Haigh, B., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Bertram, L., Murphy, Z. et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell, 125, 1179-1191.
8. Pouladi, M.A., Graham, R.K., Karasinska, J.M., Xie, Y., Santos, R. D., Petersén,ÅandHayden, M.R. (2009) Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain, 132, 919-932.
9. Tebbenkamp, A.T.N., Green, C., Xu, G., Denovan-Wright, E.M., Rising, A.C., Fromholt, S.E., Brown, H.H., Swing, D., Mandel, R.J., Tessarollo, L. et al. (2011) Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative. Hum. Mol. Genet., 20, 2770-2782.
10. Schwarze, S.R., Ho, A., Vocero-Akbani, A. and Dowdy, S.F. (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 285, 1569-1572.
11. Hällbrink, M., Florén, A., Elmquist, A., Pooga, M., Bartfai, T. and Langel, Ü. (2001) Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta, 1515, 101-109.
12. Thorén, P.E.G., Persson, D., Isakson, P., Goksör, M., Önfelt, A. and Nordén, B. (2003) Uptake of analogs of penetratin, TAT (48-60) and oligoarginine in live cells. Biochem. Biophys. Res. Commun., 307, 100-107.
13. Chéreau, D., Kodandapani, L., Tomaselli, K.J., Spada, A.P. and Wu, J.C. (2003) Structural and functional analysis of caspase active sites. Biochemistry, 42, 4151-4160.
14. Leyva, M.J., DeGiacomo, F., Kaltenbach, L.S., Holcomb, J., Zhang, N., Gafni, J., Park, H., Lo, D.C., Salvesen, G.S., Ellerby, L.M. et al. (2010) Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models. Chem. Biol., 17, 1189-1200.
15. Le, D.A., Wu, Y., Huang, Z., Matsushita, K., Plesnila, N., Augustinack, J.C., Hyman, B.T., Yuan, J., Kuida, K., Flavell, R.A. et al. (2002) Caspase activation and neuroprotection in caspase-3-deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proc. Natl. Acad. Sci. USA, 99, 15188-15193.
16. Wong, B.K.Y., Ehrnhoefer, D.E., Graham, R.K., Martin, D.D.O., Ladha, S., Uribe, V., Stanek, L.M., Franciosi, S., Qiu, X., Deng, Y. et al. Partial rescue of some features of Huntington disease in the genetic absence of caspase-6 in YAC128 mice. Neurobiol. Dis., doi:10.1016/j.nbd.2014.12.030.
17. Hult, S., Soylu, R., Björklund, T., Belgardt, B., Mauer, J., Brüning, J., Kirik, D. and Petersén, Å. (2011) Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metab., 13, 428-439.
18. Gafni, J., Papanikolaou, T., DeGiacomo, F., Holcomb, J., Chen, S., Menalled, L., Kudwa, A., Fitzpatrick, J., Miller, S. and Ramboz, S. (2012) Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J. Neurosci., 32, 7454-7465.
19. Gray, M., Shirasaki, D.I., Cepeda, C., André, V.M., Wilburn, B., Lu, X., Tao, J., Yamazaki, I., Li, S., Sun, Y.E. et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci., 28, 6182-6195.
20. Pouladi, M.A., Stanek, L.M., Xie, Y., Franciosi, S., Southwell, A. L., Deng, Y., Butland, S., Zhang,W., Cheng, S.H., Shihabuddin, L.S. et al. (2012) Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol. Genet., 21, 2219-2232.
21. Landles, C., Weiss, A., Franklin, S., Howland, D. and Bates, G. (2012) Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS Curr., doi:10.1371/4fd085bfc9973.
22. Uribe, V., Wong, B.K.Y., Graham, R.K., Cusack, C.L., Skotte, N. H., Pouladi, M.A., Xie, Y., Feinberg, K., Ou, Y., Ouyang, Y. et al. (2012) Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Hum. Mol. Genet., 21, 1954-1967.
23. Nikolaev, A., McLaughlin, T., O'Leary, D.D.M. and Tessier-Lavigne, M. (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature, 457, 981-989.
24. Houde, C., Banks, K.G., Coulombe, N., Rasper, D., Grimm, E., Roy, S., Simpson, E.M. and Nicholson, D.W. (2004) Caspase-7 expanded function and intrinsic expression level underlies strain-specific brain phenotype of caspase-3-null mice. J. Neurosci., 24, 9977-9984.
25. Berger, A.B., Sexton, K.B. and Bogyo, M. (2006) Commonly used caspase inhibitors designed based on substrate specificity profiles lack selectivity. Cell Res., 16, 961-963.
26. Chauvier, D., Ankri, S., Charriaut-Marlangue, C., Casimir, R. and Jacotot, E. (2006) Broad-spectrum caspase inhibitors: from myth to reality? Cell Death Differ., 14, 387-391.
27. Pereira, N.A. and Song, Z. (2008) Some commonly used caspase substrates and inhibitors lack the specificity required to monitor individual caspase activity. Biochem. Biophys. Res. Commun., 377, 873-877.
28. Carroll, J., Southwell, A., Graham, R., Lerch, J., Ehrnhoefer, D., Cao, L., Zhang, W., Deng, Y., Bissada, N., Henkelman, R. et al. (2011) Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. Mol. Neurodegener., 6, 59.
29. Kalchman, M.A., Koide, H.B., McCutcheon, K., Graham, R. K., Nichol, K., Nishiyama, K., Kazemi-Esfarjani, P., Lynn, F.C., Wellington, C., Metzler, M. et al. (1997) HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membraneassociated huntingtin in the brain. Nat. Genet., 16, 44-53.
30. Ehrnhoefer, D.E., Skotte, N.H., Savill, J., Nguyen, Y.T., Ladha, S., Cao, L.P., Dullaghan, E. and Hayden, M.R. (2011) A quantitative method for the specific assessment of caspase-6 activity in cell culture. PLoS ONE, 6, e27680.
31. Koffie, R.M., Farrar, C.T., Saidi, L., William, C.M., Hyman, B.T. and Spires-Jones, T.L. (2011) Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc. Natl. Acad. Sci. USA, 108, 18837-18842.
32. Jung, J.C., Mehta, A.D., Aksay, E., Stepnoski, R. and Schnitzer, M.J. (2004) In vivo mammalian brain imaging using one- and two-photon fluorescence microendoscopy. J. Neurophysiol., 92, 3121-3133.
33. Bourin, M. and Hascoët, M. (2003) The mouse light/dark box test. Eur. J. Pharmacol., 463, 55-65.
34. Marco, S., Giralt, A., Petrovic, M.M., Pouladi, M.A., Martinez-Turrillas, R., Martinez-Hernandez, J., Kaltenbach, L.S., Torres-Peraza, J., Graham, R.K., Watanabe, M. et al. (2013) Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models. Nat. Med., 19, 1030-1038.